Top

Published in:

01-12-2015 | What's New in Intensive Care

What’s new in vasopressin?

Authors: D. J. P. O’Callaghan, Anthony C. Gordon

Published in: Intensive Care Medicine | Issue 12/2015

Excerpt

Septic shock is associated with a relative deficiency of the endogenous stress hormone vasopressin. In shock states vasopressin binds to vasopressin receptors on vascular smooth muscle, producing intense vasoconstriction with minimal osmotic effects and resulting in increased blood pressure. Two recent meta-analyses report relative risks (RR) of short-term mortality in favour of vasopressin analogues compared to noradrenaline; however, using different methodologies, one group found this difference to be statistically significant (RR = 0.87, 95 % CI 0.77–0.99) [1] and the other did not (RR = 0.91, 95 % CI 0.79–1.05) [2]. The current Surviving Sepsis Campaign guidelines recommend that vasopressin may be added as an adjunct to noradrenaline in septic shock [3]. This short review aims to give an overview of the latest clinical evidence about vasopressin. …

Serpa Neto A et al (2012) Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care 16(4):R154PubMedCentralCrossRefPubMed

Polito A et al (2012) Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. Intensive Care Med 38(1):9–19CrossRefPubMed

Dellinger RP et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39(2):165–228CrossRefPubMed

Russell JA et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358(9):877–887CrossRefPubMed

Wacharasint P et al (2012) Normal-range blood lactate concentration in septic shock is prognostic and predictive. Shock 38(1):4–10CrossRefPubMed

Gordon AC et al (2012) The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest 142(3):593–605CrossRefPubMed

Morelli A et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310(16):1683–1691CrossRefPubMed

Gordon AC et al (2010) The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36(1):83–91CrossRefPubMed

Russell JA et al (2009) Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 37(3):811–818CrossRefPubMed

10.

Gordon AC et al (2014) The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med 42(6):1325–1333CrossRefPubMed

11.

Gordon AC et al (2014) Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). BMJ Open 4(7):e005866PubMedCentralCrossRefPubMed

12.

Baker C et al (2003) Corticotropin-releasing hormone immunoreactivity in human T and B cells and macrophages: colocalization with arginine vasopressin. J Neuroendocrinol 15(11):1070–1074CrossRefPubMed

13.

Russell JA et al (2013) Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med 188(3):356–364CrossRefPubMed

14.

Anantasit N et al (2014) Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock. Crit Care Med 42(8):1812–1820CrossRefPubMed

15.

Mehta S et al (2013) Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. Crit Care 17(3):R117PubMedCentralCrossRefPubMed

16.

Nakada TA et al (2011) Leucyl/cystinyl aminopeptidase gene variants in septic shock. Chest 139(5):1042–1049CrossRefPubMed

17.

Maybauer MO et al (2014) The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis. Crit Care Med 42(7):e525–e533PubMedCentralCrossRefPubMed

18.

Mentzelopoulos SD et al (2013) Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA 310(3):270–279CrossRefPubMed

19.

Hajjar L, Vincent JL, Rhodes A, Galas F, Fukushima JT, Osawa EA, Grande SM, Almeida JP, Zefferino S, Camara L, Jatene FB, Filho RK (2014) Vasopressin or norepinephrine in vasoplegia after cardiac surgery (VANCS study): a randomised, double-blind and controlled study. Intensive Care Med 40 (Suppl 1):S126

20.

Cossu AP et al (2014) Vasopressin in hemorrhagic shock: a systematic review and meta-analysis of randomized animal trials. Biomed Res Int 2014:421291PubMedCentralPubMed

Title: What’s new in vasopressin?
Authors: D. J. P. O’Callaghan
Anthony C. Gordon
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: Intensive Care Medicine / Issue 12/2015
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-015-3849-3

At a glance: The STEP trials

Springer Medicine

What’s new in vasopressin?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2015

Chasing the elusive notion of delirium causality

Prone positioning and neuromuscular blocking agents are part of standard care in severe ARDS patients: no

Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs

Early daily mHLA-DR monitoring predicts forthcoming sepsis in severe trauma patients

Nystatin versus amphotericin B to prevent and eradicate Candida colonization during selective digestive tract decontamination in critically ill patients

Large pleural effusion leading to cardiac tamponade